Lilly Prepares $1.5B Orforglipron Launch, Retevmo Shows Phase 3 Survival Win
Lilly has built a $1.5 billion inventory of oral weight-loss drug Orforglipron ahead of an April FDA decision and plans a summer marketing launch. Lilly’s Retevmo met the primary endpoint in a 151-patient Phase 3 LIBRETTO-432 adjuvant study, delivering statistically significant event-free survival benefit.
1. Orforglipron Launch Readiness
Eli Lilly has amassed $1.5 billion of inventory for its oral weight-loss candidate Orforglipron ahead of an anticipated April FDA decision, reflecting confidence in early demand. The company plans a full-scale marketing push this summer to leverage the convenience of a pill format and broaden its weight-loss market reach against injectable rivals.
2. Retevmo Phase 3 Adjuvant Trial Success
In the LIBRETTO-432 study of 151 patients with early-stage RET fusion-positive non-small cell lung cancer, Retevmo achieved a statistically significant improvement in event-free survival as adjuvant therapy. Safety data were consistent with earlier trials, and Lilly intends to pursue regulatory discussions for expanded adjuvant indications and submit full results for publication.